Thermo Fisher pledges to reach carbon neutrality by 2050

Accelerated efforts align with the Paris Agreement and Race To Zero to combat climate change
Thermo Fisher Scientific has announced its commitment to achieve net-zero carbon emissions by 2050, a decision that advances the company's current strategy to mitigate its impact on the environment.
Back in 2019, the company set targets to reduce greenhouse gas (GHG) emissions across its operations (Scopes 1 and 2) by 2030. These goals are aligned with the criteria of the Science Based Targets initiative (SBTi).
Thermo Fisher's new pledge to reach carbon neutrality by 2050 incorporates additional targets to reduce its value chain emissions (Scope 3), including a commitment to SBTi's most ambitious guidelines. It also supports the global goals of the Paris Climate Agreement and the United Nations' Race To Zero campaign.
The company has already made strides towards achieving its net zero commitment by making its facilities more energy efficient, increasing the use of renewable energy and reducing waste in its operations.
Thermo Fisher said it also plays a role in advancing climate science — its analytical instruments spur the creation of green technologies and allow researchers to further investigate global warming, all of which help enable customers and partners to achieve their climate goals.
Marc N. Casper, chairman, president and chief executive officer, Thermo Fisher Scientific, said the endeavour to reach the 2050 target will engage each member of the company's 80,000 strong workforce to address climate change.

Related News
-
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute. -
News 3 ways ChatGPT will impact pharma marketing teams
What does the rise of AI-powered chatbots such as ChatGPT and GPT-4 mean for pharma marketeers? -
News Eli Lilly, Novo Nordisk, and Sanofi cut insulin prices by up to 78%
Insulin prices have dropped in a stark play by the three biggest makers of the product, after calls from the top of the US government. -
News Open letter challenges EU Commission on medicine supply chain
In an open letter to the European Commission, Medicines for Europe calls for a new medicine security contract with their goal to improve access to medicine and ensure a secure supply chain to Europe.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance